| BACKGROUND: Osteoporosis (OP) is a degenerative bone metabolic disease with chronic aseptic inflammation associated with osteoblast-mediated bone formation and osteoclast-mediated bone resorption. At present, the drugs commonly used in the treatment of osteoporosis, such as bisphosphonates that inhibit bone resorption and calcitonin and estrogen drugs that promote bone formation, have limitations such as side effects and poor patient compliance.To summarize the mechanism and research results of STING signaling pathway in bone formation and bone resorption, and to summarize the mechanism of STING signaling pathway in bone resorption and bone formation in the treatment of osteoporosis.
METHODS: In November 2023, the first author used computers to search PubMed and CNKI databases with the terms "STING, osteoporosis, osteoblast, osteoclast, IFN-β, NF-κB, type H vessels", and "STING, osteoblast, osteoclast, IFN-β, NF-κB, H-type blood vessels" Search for Chinese search terms.
Conclusion: The unique role of STING pathway in osteoporosis provides a new direction for treatment. Activation of the STING/IFN-β signaling pathway reduces bone resorption by inhibiting osteoclast differentiation. In contrast, STING/NF-κB activation leads to the formation of osteoporosis by increasing bone resorption and decreasing bone formation. In addition, the activation of STING inhibits the production of H-type blood vessels with osteogenic ability, thus inhibiting bone formation. However, the regulatory network of STING pathway is quite complex, and its dual role in the treatment of osteoporosis needs more in-depth study. In the future, by precisely regulating different branches of the STING pathway, it is expected to develop safer and more effective osteoporosis treatments. |